The roles and regulation of MDM2 and MDMX: it is not just about p53
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Most well studied as proteins that restrain the p53 tumor suppressor protein, MDM2 and MDMX have rich lives outside of their relationship to p53. There is much to learn about how these two proteins are regulated and how they can function in cells that lack p53. Regulation of MDM2 and MDMX, which takes place at the level of transcription, post-transcription, and protein modification, can be very intricate and is context-dependent. Equally complex are the myriad roles that these two proteins play in cells that lack wild-type p53; while many of these independent outcomes are consistent with oncogenic transformation, in some settings their functions could also be tumor suppressive. Since numerous small molecules that affect MDM2 and MDMX have been developed for therapeutic outcomes, most if not all designed to prevent their restraint of p53, it will be essential to understand how these diverse molecules might affect the p53-independent activities of MDM2 and MDMX.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascón, S., Hatzios, S. K., Kagan, V. E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.021 · Cited by 7,695 · cited 2×
“2020), a potentially tumor-suppressive process (Stockwell et al. 2017), supports the suggestion that the contextdependent role of MDM2 and MDMX in tumor suppression is worth serious consideration.”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“The first such agent to be identified, nutlin, has been invaluable for the p53 research community and has the added distinction of being one of the first smallmolecules that canefficiently disrupt the interaction between two full-length proteins (Vassilev et al. 2004).”
BackgroundTP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 2×
“, melanoma, testicular cancer, sarcoma, and cervical cancer) (Olivier et al. 2010), the question is highly context dependent.”
BackgroundMutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · cited 1×
“…all such cases, tumors express high levels of mutant p53, and there is mounting evidence that in some settings, suchmutant p53 proteins are eliciting protumorigenic activities sometimes referred to as “gain of function” (Brosh and Rotter 2009; Freed-Pastor and Prives 2012;Muller and Vousden 2014).”
BackgroundMDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265 · cited 4×
“The GENES & DEVELOPMENT 579 discovery that SNP309 and SNP55 each affect the binding affinity of the Sp1 transcription factor to their respective regions in the MDM2 promoter provides a model for how suchmechanistic information could be obtained.”
BackgroundInfluentialWhen mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132 · cited 2×
“In many but not all such cases, tumors express high levels of mutant p53, and there is mounting evidence that in some settings, suchmutant p53 proteins are eliciting protumorigenic activities sometimes referred to as “gain of function” (Brosh and Rotter 2009; Freed-Pastor and Prives 2012;Muller and Vousden 2014).”
BackgroundMdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53
Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H., & Weissman, A. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8945 · Cited by 1,044
Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2
Li, M., Brooks, C. L., Wu-Baer, F., Chen, D., Baer, R., & Gu, W. (2003) · Science · doi:10.1126/science.1091362 · Cited by 804 · cited 1×
“As described earlier in this review, MDM2 is able to regulate different aspects of its E3 ligase targets, including p53, outside of mere degradation depending on whether it performs polyubiquitylation or monoubiquitylation (Li et al. 2003; Marine and Lozano 2010).”
BackgroundSignaling to p53: ribosomal proteins find their way
Zhang, Y., & Lu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.024 · Cited by 591 · cited 1×
“It has been established for some time that MDM2 binds to an extraordinary number of ribosomal proteins (RPs) (Zhang and Lu 2009; Deisenroth et al. 2016).”
BackgroundThe p53 orchestra: Mdm2 and Mdmx set the tone
Wade, M., Wang, Y. V., & Wahl, G. M. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.01.009 · Cited by 450
Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development
Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000657 · Cited by 395 · cited 2×
“For example, the clinical activity of RG7112, a molecule that exert its effects via competitive binding to the p53 pocket ofMDM2 (Vu et al. 2013), inAML patients correlated with the expression levels of MDM2 but not the status of p53 (Andreeff et al. 2016).”
BackgroundAccelerated MDM2 auto‐degradation induced by DNA‐damage kinases is required for p53 activation
Stommel, J. M., & Wahl, G. M. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600145 · Cited by 386
HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53
Linares, L. K., Hengstermann, A., Ciechanover, A., Müller, S., & Scheffner, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2030930100 · Cited by 361 · cited 2×
“576 GENES & DEVELOPMENT Instead, MDMXmight then focus the E3 ligase activity of MDM2 against its other targets, which has been supported experimentally (Linares et al. 2003; Kawai et al. 2007; Linke et al. 2008; Okamoto et al. 2009), thereby making the MDM2–MDMX heterocomplex a better E3 ligase.”
BackgroundResults of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia
Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0481 · Cited by 352
The Mdm2–p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor
Manfredi, J. J. (2010) · Genes & Development · doi:10.1101/gad.1941710 · Cited by 344
Linke, K., Mace, P. D., Smith, C. A., Vaux, D. L., Silke, J., & Day, C. L. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402309 · Cited by 288 · cited 8×
“…of MDMX has not been studied as extensively; nevertheless, in addition to the established MDM2-mediated ubiquitination of MDMX at K442 (Linke et al. 2008), Peli1, another E3 ligase, binds and polyubiquitinates MDMX, resulting in translocation of MDMX to the cytoplasm in a…”
BackgroundMethodInfluentialThe Role of MDM2 Amplification and Overexpression in Tumorigenesis
Oliner, J. D., Saiki, A. Y., & Caenepeel, S. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026336 · Cited by 246 · cited 3×
“SNPs Coupled with discoveries of transcription factors that can regulate the gene have been reports of naturally occurring genetic MDM2 variants in the form of singlenucleotide polymorphisms (SNPs) that regulate its gene expression (for review, see Oliner et al. 2016).”
BackgroundInfluentialItahana, K., Mao, H., Jin, A., Itahana, Y., Clegg, H. V., Lindström, M. S., Bhat, K. P., Godfrey, V. L., Evan, G. I., & Zhang, Y. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.09.007 · Cited by 245
Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms
Stad, R., Little, N. A., Xirodimas, D. P., Frenk, R., van der Eb, A. J., Lane, D. P., Saville, M. K., & Jochemsen, A. G. (2001) · The EMBO Reports · doi:10.1093/embo-reports/kve227 · Cited by 234
MDM2 Promotes Cell Motility and Invasiveness by Regulating E-Cadherin Degradation
Yang, J.-Y., Zong, C. S., Xia, W., Wei, Y., Ali-Seyed, M., Li, Z., Broglio, K., Berry, D. A., & Hung, M.-C. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00172-06 · Cited by 211 · cited 3×
“MDM2 also drives the EMT through the TGF-β–Smad pathway in ovarian cancer by promoting Snail/Slug expression and activating Smad2/3 (Chen et al. 2017).”
BackgroundPoyurovsky, M. V., Priest, C., Kentsis, A., Borden, K. L., Pan, Z., Pavletich, N., & Prives, C. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601465 · Cited by 203 · cited 2×
“While in MDM2 alone these mutations can also block its E3 ligase activity, the extreme C terminus of MDMX can rescue the E3 ligase ability of such Cterminal mutant forms of MDM2 (Poyurovsky et al. 2007; Singh et al. 2007; Uldrijan et al. 2007).”
BackgroundThe p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo
Huang, L., Yan, Z., Liao, X., Li, Y., Yang, J., Wang, Z.-G., Zuo, Y., Kawai, H., Shadfan, M., Ganapathy, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102309108 · Cited by 193 · cited 1×
“There are also five residues at the extreme C termini of both proteins (outside of their RINGs) that are essential for these complexes to be stably formed (Poyurovsky et al. 2007; Uldrijan et al. 2007; Huang et al. 2011).”
BackgroundHDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function
Lau, L. M. S., Nugent, J. K., Zhao, X., & Irwin, M. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210707 · Cited by 182 · cited 2×
“While nutlin and the many subsequent drugs that were developed to specifically separate MDM2 (and more rarely MDMX) from p53 have not generally been considered useful outside the context of p53, even nutlin can disrupt MDM2 from binding the p53 homolog p73 (Lau et al. 2008), as well as E2F (Ambrosini et al.”
BackgroundAn essential function of the extreme C-terminus of MDM2 can be provided by MDMX
Uldrijan, S., Pannekoek, W., & Vousden, K. H. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601469 · Cited by 170
Ambrosini, G., Sambol, E. B., Carvajal, D., Vassilev, L. T., Singer, S., & Schwartz, G. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210136 · Cited by 163 · cited 3×
“In the above-mentioned studies, Kundu et al. (2017) place MDM2 activity within an estrogen-MDM2-Rb-E2F1 pathway, while Feeley et al. (2017) report thatMDM2 acts through inhibition of p73.”
BackgroundBrown, D. R., Thomas, C. A., & Palit Deb, S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.9.2513 · Cited by 148
MDM2-ARF complex regulates p53 sumoylation
Chen, L., & Chen, J. (2003) · Oncogene · doi:10.1038/sj.onc.1206851 · Cited by 134 · cited 1×
“In brief, MDM2 (which itself can SUMOylate other substrates) can be SUMOylated at K446; thismodification inhibits ubiquitination ofMDM2, including autoubiquitination, and stabilizes the protein (Chen and Chen 2003; Stindt et al. 2011; Li and Kurokawa 2015).”
BackgroundSolution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53
Kostic, M., Matt, T., Martinez-Yamout, M. A., Dyson, H. J., & Wright, P. E. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.08.027 · Cited by 128 · cited 1×
“The structures of the MDM2 and MDMXRING domains have been solved by NMR (Kostic et al. 2006) and X-ray crystallography (Linke et al. 2008).”
MethodA High-Frequency Regulatory Polymorphism in the p53 Pathway Accelerates Tumor Development
Post, S. M., Quintás-Cardama, A., Pant, V., Iwakuma, T., Hamir, A., Jackson, J. G., Maccio, D. R., Bond, G. L., Johnson, D. G., Levine, A. J., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.07.010 · Cited by 127
Banks, D., Wu, M., Higa, L. A., Gavrilova, N., Quan, J., Ye, T., Kobayashi, R., Sun, H., & Zhang, H. (2006) · Cell Cycle · doi:10.4161/cc.5.15.3150 · Cited by 127
A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis
Wang, H., Ma, X., Ren, S., Buolamwini, J. K., & Yan, C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0581 · Cited by 117
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
Fang, Y., Liao, G., & Yu, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.003 · Cited by 106 · cited 1×
“…underway for many years, GENES & DEVELOPMENT 585 albeit in the context of blocking the abilities of these two proteins to inhibit p53, and by now, numerous pharmacological antagonists have been designed to reactivate p53 for cancer treatment (Qin et al. 2012; Tisato et al. 2017; Fang et al. 2020).”
BackgroundDiscovery of Mdm2-MdmX E3 Ligase Inhibitors Using a Cell-Based Ubiquitination Assay
Herman, A. G., Hayano, M., Poyurovsky, M. V., Shimada, K., Skouta, R., Prives, C., & Stockwell, B. R. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0104 · Cited by 100
Self-citationRegulation of MDMX Expression by Mitogenic Signaling
Gilkes, D. M., Pan, Y., Coppola, D., Yeatman, T., Reuther, G. W., & Chen, J. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01633-07 · Cited by 82
Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.
Nihira, N. T., Ogura, K., Shimizu, K., North, B. J., Zhang, J., Gao, D., Inuzuka, H., & Wei, W. (2017) · Science Signaling · doi:10.1126/scisignal.aai8026 · Cited by 82 · cited 5×
“However, MDM2 can increase DNA accessibility via degradation of the major methyltransferase suppressor of variegation 3-9 homolog 1 (SUV39H1), which is opposed by USP7 deubiquitination of SUV39H1 (Mungamuri et al. 2016).”
BackgroundInfluentialMdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase
Okamoto, K., Taya, Y., & Nakagama, H. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.07.021 · Cited by 76
Meek, D. W., & Hupp, T. R. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.005 · Cited by 76 · cited 1×
“Because of the importance of phosphorylation to MDM2 functions, especially during DNA damage, this subject has been comprehensively reviewed (Meek and Knippschild 2003; Meulmeester et al. 2005; Meek and Hupp 2010; Wade et al. 2010; Markey 2011; Li and Kurokawa 2015; Carr and Jones 2016).”
BackgroundMdmX inhibits ARF mediated Mdm2 sumoylation
Ghosh, M., Weghorst, K., & Berberich, S. J. (2005) · Cell Cycle · doi:10.4161/cc.4.4.1597 · Cited by 71
Mdmx promotes genomic instability independent of p53 and Mdm2
Carrillo, A. M., Bouska, A., Arrate, M. P., & Eischen, C. M. (2015) · Oncogene · doi:10.1038/onc.2014.27 · Cited by 69 · cited 3×
“Additionally, MDMX both plays a role in genome instability via association with Nbs1 (Carrillo et al. 2015) and also potentially plays a crucial role in DNA replication; its loss delays replication fork progression and sensitizes tumor cells to gemcitabine, suggesting that it may play a role in…”
BackgroundInfluentialThe p53/MDM2/MDMX-targeted therapies – a clinical synopsis
Jiang, L., & Zawacka-Pankau, J. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2445-9 · Cited by 62
Matijasevic, Z., Steinman, H. A., Hoover, K., & Jones, S. N. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01108-07 · Cited by 58 · cited 1×
“While MDMX, like MDM2, is typically considered an oncogene and is amplified in many cancers, basal expression ofMDMXhas numerous antitumor effects in thymus and breast cancers lacking p53: MDMX suppresses proliferation in p53-null thymic tumors (Matijasevic et al. 2008).”
BackgroundPhillips, A., Teunisse, A., Lam, S., Lodder, K., Darley, M., Emaduddin, M., Wolf, A., Richter, J., de Lange, J., Verlaan-de Vries, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.129726 · Cited by 55 · cited 1×
“Interestingly, MDMX also possesses a main promoter (P1) as well as a second promoter (P2) within the first intron that can be regulated by p53 and that generates a novel transcript (HDMX-L) whose product cooperates with MDM2 to efficiently degrade p53 (Phillips et al. 2010).”
BackgroundVaseva, A. V., Yallowitz, A. R., Marchenko, N. D., Xu, S., & Moll, U. M. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.39 · Cited by 55
Chargari, C., Leteur, C., Angevin, E., Bashir, T., Schoentjes, B., Arts, J., Janicot, M., Bourhis, J., & Deutsch, E. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.011 · Cited by 54 · cited 1×
“Taken together with the study where serdemetan elicited an anticancerous response in multiple patient-derived xenografts harboring either mutant or wild-type p53 (Chargari et al. 2011), there is a need for additional research into its clinical effectiveness.”
BackgroundMungamuri, S. K., Qiao, R. F., Yao, S., Manfredi, J. J., Gu, W., & Aaronson, S. A. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.049 · Cited by 54 · cited 1×
“However, MDM2 can increase DNA accessibility via degradation of the major methyltransferase suppressor of variegation 3-9 homolog 1 (SUV39H1), which is opposed by USP7 deubiquitination of SUV39H1 (Mungamuri et al. 2016).”
BackgroundIFN Regulatory Factor 8 Regulates MDM2 in Germinal Center B Cells
Zhou, J. X., Lee, C. H., Qi, C. F., Wang, H., Naghashfar, Z., Abbasi, S., & Morse, H. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803693 · Cited by 47
SIRT7 activates p53 by enhancing PCAF-mediated MDM2 degradation to arrest the cell cycle
Lu, Y.-F., Xu, X.-P., Lu, X.-P., Zhu, Q., Liu, G., Bao, Y.-T., Wen, H., Li, Y.-L., Gu, W., & Zhu, W.-G. (2020) · Oncogene · doi:10.1038/s41388-020-1305-5 · Cited by 40
Jones, R. J., Gu, D., Bjorklund, C. C., Kuiatse, I., Remaley, A. T., Bashir, T., Vreys, V., & Orlowski, R. Z. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.204958 · Cited by 26
Cited by
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches
Liu, F., Chen, J., Li, K., Li, H., Zhu, Y., Zhai, Y., Lu, B., Fan, Y., Liu, Z., Chen, X., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02046-3 · Cited by 326
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Pharmacological reactivation of p53 in the era of precision anticancer medicine
Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M., & Wiman, K. G. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00842-2 · Cited by 93
Small-molecule correctors and stabilizers to target p53
Fallatah, M. M. J., Law, F. V., Chow, W. A., & Kaiser, P. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.007 · Cited by 44
MDM2 inhibition in the treatment of glioblastoma: From concept to clinical investigation
Pellot Ortiz, K. I., Rechberger, J. S., Nonnenbroich, L. F., Daniels, D. J., & Sarkaria, J. N. (2023) · Biomedicines · doi:10.3390/biomedicines11071879 · Cited by 30
Metadata
- Authors
- Klein, A. M., de Queiroz, R. M., Venkatesh, D., & Prives, C.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2021-04-22
- Volume
- 35
- Issue
- 9-10
- Pages
- 575-601
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W3153502267
- Cited by
- 129
- References
- 49
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.